프리마켓
로그인 회원가입
CVM
CVM
Cel-Sci Corp
7월 27일 4:00 PM ET (한국 7/28 05:00)
$1.18
+0.00 +0.00%
🌙 7월 28일 7:07 AM ET (한국 7/28 20:07)
$1.23
+0.05 ▲ +4.24%

셀-사이(CVM) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독
시가총액
$21M
스몰캡
P/E
-
배당수익률
없음
52주 위치
2%
저점 +33% · 고점 -91%
애널리스트
적극 매수
C+
Fundamental health
vs. Biotechnology· based on 2 axes
수익성
산출 불가 (적자)
성장
Top 28%
밸류에이션
데이터 부족
재무 안정
Top 77%
Index -P/E -EPS (ttm) -3.48Insider Own 7.7%Shs Outstand 17.5MPerf Week -7.09%
Market Cap 0.02BForward P/E -EPS next Y -Insider Trans 42.3%Shs Float 16.1MPerf Month 21.1%
Enterprise Value 0.03BPEG -EPS next Q -Inst Own 4.41%Short Float 4.45%Perf Quarter -63.13%
Income -0.02BP/S -EPS this Y -Inst Trans -0.37%Short Ratio 1.31Perf Half Y -79.76%
Sales 0.00BP/B 1.46EPS next 5Y 25.29%ROA -114.9%Short Interest 0.72MPerf YTD -77.57%
Book/sh 0.81P/C 10.91EPS past 3/5Y 37.9% 23.99%ROE -305.27%52W High -91.24% ($13.48)Perf Year -85.61%
Cash/sh 0.11P/FCF -Sales past 3/5Y -ROIC -177.71%52W Low 32.58% ($0.89)Perf 3Y -97.7%
Dividend Est. -EV/EBITDA -EPS Y/Y TTM 71.62%Gross Margin -Volatility(W/M) 8.8% 11.09%Perf 5Y -99.51%
Dividend TTM -EV/Sales -Sales Y/Y TTM -Oper. Margin -ATR (14) 0.13Perf 10Y -99.67%
Dividend Ex-Date -Quick Ratio 0.54EPS Q/Q 71.2%Profit Margin -RSI (14) 45.35Recom 1
Dividend Gr. 3/5Y -Current Ratio 0.6Sales Q/Q -SMA20 -2.24% ($1.21)Beta 0.62Target Price $15
Payout -Debt/Eq 1.24Earnings 2026/5/18SMA50 -6.6% ($1.26)Rel Volume 0.27Prev Close $1.18
Employees -LT Debt/Eq 0.86EPS/Sales Surpr. -SMA200 -72.59% ($4.3)Avg Volume(3M) 0.55MPrice $1.18
IPO 1983/12/8Option/Short No/YesTrades 464Volume 146,707Change -
Quarterly earnings trend SEC filings · USD
23.12
24.3
24.6
24.12
25.3
25.6
25.12
26.3
Revenue Net income 최근 분기: 매출 - · 순이익 $-5M (YoY +17%)

📊 Cel-Sci Corp (CVM) Investment Analysis

What kind of company is Cel-Sci Corp?

셀-사이(CVM) 성장주
Healthcare · Biotechnology
Small-Cap — Low Volume, High Volatility

🧬 This is a U.S. clinical-stage biotech company developing Multikine, an immunotherapy designed to improve treatment outcomes for head and neck cancer patients through pre-surgical (neoadjuvant) immunotherapy.

Learn more about Cel-Sci Corp →
Market Cap
$0.0B
Approx. KRW 0.0 trillion
⚖️ 0% of Samsung Electronics
Market Cap Rank5255
IPO1983/12/08
Current Price$1.18 ≈ 1,617원
AMEX · USA

Key Events

⏰ Upcoming events
🔔 Earnings release
The next release date has not been announced yet.
🎯 Ex-dividend date
No scheduled dividends
📜 Recent events
🔔 Earnings release 2026년 5월 18일 (월) · 장 시작 전
🔔 Earnings release 2026년 2월 18일 (수) · 장 시작 전

Is it profitable?

Both profitability & finances need caution
Review management risk carefully before investing
Profitability — How efficiently it makes money
ROE
Annual return earned on shareholders' equity (15%+ is strong)
-305.3%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
ROA
Annual earnings relative to total company assets
-114.9%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
ROIC
Return generated per dollar invested in the business
-177.7%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
Financial health — Debt & liquidity burden
Debt-to-Equity (D/E)
Debt relative to equity (lower is healthier)
1.24
✓ Average
My positionMid-range
Low range Average High range
Biotechnology Median 0.05
💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)
Current Ratio
Liquid assets available to cover liabilities due within a year
0.60
✓ 매우 부진
My positionBottom 5%
Low range Average High range
Biotechnology Median 5.75
💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의
Quick Ratio
Liquid assets excluding inventory, available for immediate use
0.54
✓ 매우 부진
My positionBottom 5%
Low range Average High range
Biotechnology Median 5.47
💡 1.0 이상이면 안전, 0.5 미만이면 주의
* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Mixed Outlook
Positive and negative signals are mixed
애널리스트 목표가
$15.00
현재가 대비 +1171.2%
💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균
5년 EPS 예상 연평균
+25.3%
💡 장기 성장 전망. 15% 이상이면 고성장 기업
⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

Insufficient historical earnings data

No analyzable past earnings releases have been collected yet.

Is it growing?

Strong Growth
Above the industry average, both historically and going forward
🔮 How much will it grow? (analyst forecasts)
5-Year EPS CAGR Outlook
Projected average annual EPS growth over the next 5 years
+25.3%
우수
My positionTop 25%
Low range Average High range
성장주 초소형주 Median 21.6% · Top 23%
📊 How much has it grown? (actual results)
Past 3-Year EPS
Actual average annual EPS growth over the past 3 years
+37.9%
양호
My positionMid-range
Low range Average High range
성장주 초소형주 Median 24.8% · Top 31%
Past 5-Year EPS
Actual average annual EPS growth over the past 5 years
+24.0%
양호
My positionMid-range
Low range Average High range
성장주 초소형주 Median 12.0% · Top 30%
* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

Has the stock risen over the long term?

Long-term weakness — -168%p below the market
CVM -99.5% · S&P 500 +68.4%
Excess return vs. market (price-based, ex-dividends)
5-year basis
vs S&P 500
-167.9%p
Significantly behind the market
vs Health Care (XLV)
-124.0%p
Significantly behind the sector average
1-year basis
vs S&P 500
-101.6%p
Significantly behind the market
vs Health Care (XLV)
-105.3%p
Significantly behind the sector average
Rank among peers
5-year return Bottom 22% Based on 245 peers
1-year return Bottom 17% Based on 315 peers
Current position within 52-week range
Low (-32.6%p) High (-91.2%p)
Current price is 32.6% above the 52-week low and 91.2% below the 52-week high
Recent risk (last 120 trading days)
Max drawdown
-81.5%
Annualized volatility
123.0%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

  • close
  • BB Upper
  • BB Mid
  • BB Lower
  • Tenkan
  • Kijun
  • Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🔴
Current diagnosis · 2026-07-27
Downtrend zone

Current price $1.18 below the midline ($1.21). Normal downward flow. Below the Ichimoku cloud (bearish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🟡
Current diagnosis · 2026-07-27
Neutral zone — weak trend

MACD -0.031 · Signal -0.044 · Hist 0.013. Weak directional bias.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🔴
Current diagnosis · 2026-07-27
Bearish zone

RSI 45.4 (below the neutral level of 50). Selling pressure leads, indicating a weak trend. Stoch %K is also 28.2.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

In line with the industry average
In line with peers on Vs. Assets
💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.
🏢 Vs. Assets Mid-range
🏢 Vs. Assets
PBR Price-to-Book Ratio
Price vs. the company's asset value — below 1 trades cheaper than assets
1.46x
✓ Fair
My positionMid-range
Low range Average High range
Biotechnology 초소형주 median 1.35x · Around the industry average
💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)
Analyst target price (reference)
$15.00 vs. current price +1171.2%
* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.
As of: Recent snapshot · Peer group: Biotechnology 초소형주

Who owns it?

Ownership flow is positive
Insider net buying +42.3% · Institutional modest net selling -0.4% · Short interest light 4.5% · Short interest fell -2.0%p over the last 88 days
📈 Recent trading flow (6 months)
🧑‍💼 Insiders (executives & directors)
+42.3%
Insiders large net buying
🏦 Institutions (funds & investors)
-0.4%
Institutions net selling
💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.
👥 Holdings composition
🏦 Institutions 4.4%
Retail-led
Healthcare 초소형주 Median 14.2%
🧑‍💼 Insiders 7.7%
Meaningful insider stake
Healthcare 초소형주 Median 16.1%
👤 Retail investors (estimated) 87.9%
Everyone excluding institutions and insiders
Institutions Insiders Retail (est.)
📉 Short-selling metrics
Short ratio
4.5%
Low — limited short-side pressure
Healthcare 초소형주 Median 3.9%
Past 88 days 📉 -2.0%p decrease
Short interest days to cover
1.3 days
Days needed to close short positions using average trading volume
🧮 Share count
Total shares outstanding 17.5M주
Float (tradable shares) 16.1M주
* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 88 days.

ETFs holding CVM

* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)
Sorted by market cap, largest first
StockMarket CapPERPBRROEDividend YieldChange
CVM CVM This Stock
$20.6M- 1.5 -305.27% - +0.0%
LLY
$1.13T43.1 36.2 107.64% 0.58% +0.1%
JNJ
$640.9B30.8 7.5 25.74% 2.02% +1.0%
ABBV
$453.9B126.7 - 15221.82% 2.67% -0.9%
UNH
$379.3B26.9 3.9 12.49% 2.16% -0.7%
MRK
$323.0B36.8 7.0 18.97% 2.5% -0.2%
Sector Avg-26.12.7-48.83%1.23%-
📊
See the market at a glance with a real-time dashboard Track premarket, regular, and after-hours quotes, screeners, and heatmaps on a single screen

FAQ

What kind of company is 셀-사이(CVM)?

셀-사이(CVM) belongs to the Healthcare sector and operates in the Biotechnology industry.

What is the market cap of CVM?

The market cap of CVM is approximately $21M, ranking 5,255 within its sector.

What is the 52-week high and low for CVM?

CVM has recorded a 52-week high of $13.48 and a low of $0.89.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.